We assessed the relationship between [18F]AV-1451 uptake on PET with tau burden at autopsy, and with measures of neurodegeneration from [18F]fluorodeoxyglucose (FDG) PET and MRI, in a patient with autopsy-confirmed CBD as well as performed correlative autoradiography, as previously described [6] . The male patient died aged 59 after a 10-year history of progressive neurological decline. He first presented with difficulty getting his words out and was diagnosed with primary progressive apraxia of speech [5] . Over time, he developed difficulty with language, swallowing difficulties, ideomotor apraxia, marked parkinsonism, and balance and gait problems (Online resource 1), hence his clinical diagnosis was later changed to corticobasal syndrome [1] . He tested negative for microtubuleassociated protein tau mutations. Autopsy revealed 4R tau-positive, but 3R tau-negative threads in grey and white matter of cortex, basal ganglia, thalamus and brainstem, as well as pretangles, astrocytic plaques and coiled bodies (oligodendroglial inclusions) consistent with a diagnosis of CBD [3] (Fig. 1a , Online Resource 1). Fourteen months prior to death, he underwent [18F]AV-1451 PET, as well as Pittsburgh-compound B (PiB) PET, FDG-PET and a 3T volumetric MRI. In addition, he had undergone MRI scans 9 and 22 months before death.
We abstracted tau burden at autopsy, tau-PET uptake, FDG-PET uptake, grey matter volumes and grey matter rates of atrophy for the identical set of ten regions-of-interest (ROIs) in the left hemisphere (middle frontal, supplementary motor area, primary motor, Broca's area, orbitofrontal cortex, inferior parietal, superior temporal, parahippocampal gyrus, visual cortex and striatum). Tau burden at autopsy was determined quantitatively. All ten ROIs were scanned at ultra-resolution on the ScanScopeXT from which large areas of interest were annotated using ImageScope-11.2 (Aperio Technologies, Vista, CA). Annotated regions were Corticobasal degeneration (CBD) is a neurodegenerative disease characterized by the deposition of abnormally hyperphosphorylated 4-repeat (4R) tau in the brain [3] . Recent advances in molecular neuroimaging include the production of positron emission tomography (PET) ligands that bind to abnormal tau in the brain. One such ligand, [18F]AV-1451, has been shown to bind to abnormal 3R + 4R tau in diseases such as Alzheimer's disease [2] . In addition, one case report found an association between antemortem [18F]AV-1451 and tau burden in an autopsied case with a mutation in the microtubule-associated protein tau gene with 3R + 4R tau [9] . Autoradiographic studies however have found very little, if any, binding in diseases characterized by 4R-tau including CBD [6] [7] [8] , and no PETautopsy studies have been published for a 4R-tau disease.
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The online version of this article (doi:10.1007/s00401-016-1618-1) contains supplementary material, which is available to authorized users. analyzed in Spectrum-11.2 using a custom-designed color deconvolution algorithm to detect only abnormal tau [4] (Fig. 1a) . Tau burden was expressed as the area of immunoreactive pixels to the total area of the annotated region. The automated anatomical labeling atlas was used to output ROI data from neuroimaging (Online Resource 2). To create standard uptake ratios (SUVRs), tau-PET uptake in each ROI was divided by uptake in cerebellar crus grey matter, and FDG-PET uptake was divided by uptake in pons. Grey matter volumes were divided by total intracranial volume and were expressed as z-scores representing difference from ten cognitively normal male controls that were the same age as our patient. In addition, annualized regional rates of atrophy were calculated using tensor-based morphometry using the serial scans that straddled the time of the tau-PET scan, i.e., those performed 9 and 22 months before death (Online Resource 2). Spearman rank correlations were calculated using JMP software (JMP Software, version 10.0.0; SAS Institute Inc, Cary, NC) with α = 0.05. Tau-PET revealed increased signal in putamen, pallidum, thalamus, precentral cortex, rolandic operculum, supplemental motor area, and left Broca's area (Fig. 2) . The PiB-PET scan was negative (Fig. 2) (global PiB SUVR = 1.28). Regional tau-PET SUVR values strongly correlated with autopsy tau burden across the 10 ROIs (r = 0.89, p = 0.0005) (Fig. 1c) . Tau-PET SUVRs showed non-significant correlations with FDG-PET (r = −0.50, p = 0.14), grey matter volume (r = −0.43, p = 0.21) and rates of atrophy (r = −0.43, p = 0.21) (Fig. 1c). [18F] AV-1451 autoradiography revealed minimal, displaceable binding in areas where dense 4R tau deposition was observed on immunohistochemistry (Fig. 1b) .
Regional [18F]AV-1451 uptake showed an excellent correlation with underlying, quantitatively measured, 4R-tau burden in our case, that did not appear to be driven by neurodegeneration. With-that said, there does appear to be a disconnect between antemortem and postmortem binding to 4R tau pathology. Furthermore, our correlative c Scatter-plots of the relationship between tau-PET SUVR and tau burden at autopsy, FDG-PET SUVR, MRI z-scores, and MRI rates of atrophy. The tau-PET data used in the correlation with tau burden at autopsy was calculated over grey and white matter within the ROI, whereas the tau-PET data used in the imaging plots was calculated over grey matter only to match the FDG and MRI data autoradiographic study reveals that the ligand may be binding only a very small fraction of the total 4R-tau burden. More work is therefore needed to better understand the relationship between [18F]AV-1451 and 4R tau, and to determine whether [18F]AV-1451 could be a disease biomarker to study CBD. 
